Hui Yu1, Yu-Xin Du1, Zhen-Chang Sun1, Xiao-Rui Fu1, Nan Tan2, Wei-Feng Gong2, Ming-Zhi Zhang1. 1. Department of Oncology, Zhengzhou University First Affiliated Hospital; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou 450052, Henan Province, China. 2. Department of Ophthalmology, Zhengzhou University First Affiliated Hospital, Zhengzhou 450052, Henan Province, China.
Abstract
AIM: To investigate the clinical features, treatment and prognosis of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (POAML). METHODS: A retrospective analysis was performed on 64 patients with POAML who were admitted to the First Affiliated Hospital of Zhengzhou University from January 2006 to December 2018. RESULTS: With a median follow-up of 61mo (range, 2-156mo), estimated overall survival (OS) rate and progression-free survival (PFS) rate at 10y reached 94.5% and 61.5%, respectively. Median OS time and PFS time were not reached. During this period, only 3 patients died, but none of them died directly due to disease progression. One patient (1.6%) developed transformation to diffuse large B-cell lymphoma (DLBCL). Of the 56 patients achieved complete remission after first-line treatment, 5 (8.9%) developed local and/or systemic relapse eventually. Patients ≥60y had significantly shorter PFS than younger patients (P=0.01). For patients with early stages (Ann Arbor stage I and stage II), univariate analysis confirmed that radiotherapy dose lower than 32 Gy were independently associated with shorter PFS (P=0.04). Other factors including gender, bone marrow involvement, the initial location of the disease, and the laterality were not associated with PFS. CONCLUSION: The data from our center indicate that POAML has a slow clinical progression and has an excellent clinical outcome. Patients with POAML harbor a continual risk of relaps and transformation to aggressive subtype of lymphoma. International Journal of Ophthalmology Press.
AIM: To investigate the clinical features, treatment and prognosis of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (POAML). METHODS: A retrospective analysis was performed on 64 patients with POAML who were admitted to the First Affiliated Hospital of Zhengzhou University from January 2006 to December 2018. RESULTS: With a median follow-up of 61mo (range, 2-156mo), estimated overall survival (OS) rate and progression-free survival (PFS) rate at 10y reached 94.5% and 61.5%, respectively. Median OS time and PFS time were not reached. During this period, only 3 patients died, but none of them died directly due to disease progression. One patient (1.6%) developed transformation to diffuse large B-cell lymphoma (DLBCL). Of the 56 patients achieved complete remission after first-line treatment, 5 (8.9%) developed local and/or systemic relapse eventually. Patients ≥60y had significantly shorter PFS than younger patients (P=0.01). For patients with early stages (Ann Arbor stage I and stage II), univariate analysis confirmed that radiotherapy dose lower than 32 Gy were independently associated with shorter PFS (P=0.04). Other factors including gender, bone marrow involvement, the initial location of the disease, and the laterality were not associated with PFS. CONCLUSION: The data from our center indicate that POAML has a slow clinical progression and has an excellent clinical outcome. Patients with POAML harbor a continual risk of relaps and transformation to aggressive subtype of lymphoma. International Journal of Ophthalmology Press.
Authors: Tine Gadegaard Hindsø; Bita Esmaeli; Frederik Holm; Lauge Hjorth Mikkelsen; Peter Kristian Rasmussen; Sarah E Coupland; Paul T Finger; Gerardo F Graue; Hans E Grossniklaus; Santosh G Honavar; Jwu Jin Khong; Penelope A McKelvie; Kaustubh Mulay; Lene Dissing Sjö; Geeta K Vemuganti; Bradley A Thuro; Steffen Heegaard Journal: Br J Ophthalmol Date: 2019-06-08 Impact factor: 4.638
Authors: Richard W Tsang; Mary K Gospodarowicz; Melania Pintilie; Woodrow Wells; David C Hodgson; Alexander Sun; Michael Crump; Bruce J Patterson Journal: J Clin Oncol Date: 2003-11-15 Impact factor: 44.544
Authors: Marco Zschoche; Annette Zimpfer; Björn O Scheef; Anselm M Jünemann; Rudolf F Guthoff; Christian Junghanss; Guido Hildebrandt; Steffen Emmert; Andreas Erbersdobler; Günther Kundt; Vinodh Kakkassery Journal: In Vivo Date: 2020 Jul-Aug Impact factor: 2.155